TCT

Transcatheter Cardiovascular Therapeutics, held Sept. 16 to 19 in Boston, featured the latest clinical science in interventional cardiology, as well as forums on innovative technologies, regulatory matters and other topics.

Healio and Cardiology Today have compiled a list of the most-read news in CV intervention from TCT 2022.

BOSTON — PCSK9 inhibition before primary PCI for STEMI, on top of standard statin therapy, significantly lowered LDL at 6 weeks compared with sham control, according to the results of the EPIC-STEMI trial presented at TCT 2022.

BOSTON — In this Healio video exclusive, B. Hadley Wilson, MD, FACC, discussed late-breaking research in transcatheter aortic valve replacement, and more presented at TCT 2022.

BOSTON — After 2 years, PCI with amphilimus-eluting stents was noninferior to PCI with zotarolimus-eluting stents in patients with diabetes, not confirming the potential superiority signal observed at 1 year.

BOSTON — In the Healio video exclusive, Roxana Mehran, MD, discussed late-breaking research presented at TCT 2022, as well as the benefits of convening the meeting in person following the COVID-19 pandemic.

BOSTON — In patients with aortic stenosis, a greater degree of cardiac damage before transcatheter or surgical aortic valve replacement increased the likelihood of poor quality of life outcomes after the procedure, researchers reported.

Medtronic announced it received FDA approval for its provisional bifurcation stenting technique utilizing a single drug-eluting stent for non-left main bifurcation lesions.

BOSTON — In the Healio video exclusive, Cardiology Today Intervention Section Editor Deepak L. Bhatt, MD, MPH, discussed late breaking research in renal and pulmonary artery denervation and other trials presented at TCT 2022.

BOSTON — Addition of fractional flow reserve to the classic SYNTAX score enabled researchers to identify patients with multivessel CAD undergoing PCI who would have similar 1-year outcomes as those who received CABG, a speaker reported.